Published on Oct. 24, 2017 in Oncotarget volume 8(58).

PubMed ID: 29228737

DOI: 10.18632/oncotarget.22041

Abstract:

The mA mRNA methylation involves in mRNA splicing, degradation and translation. Recent studies have revealed that reduced mA mRNA methylation might promote cancer development. However, the role of mA mRNA methylation in cervical cancer development remains unknown. Therefore, we investigated the role of mA methylation in cervical cancer in the current study. We first evaluated the mA mRNA methylation level in 286 pairs of cervical cancer samples and their adjacent normal tissues by dot blot assay. Then the role of mA on patient survival rates and cervical cancer progression were assessed. The mA level was significantly reduced in the cervical cancer when comparing with the adjacent normal tissue. The mA level reduction was significantly correlated with the FIGO stage, tumor size, differentiation, lymph invasion and cancer recurrence. It was also shown to be an independent prognostic indicator of disease-free survival and overall survival for patients with cervical cancer. Reducing mA level via manipulating the mA regulators expression promoted cervical cancer cell proliferation. And increasing mA level significantly suppressed tumor development both and . Our results showed that the reduced mA level is tightly associated with cervical cancer development and mA mRNA methylation might be a potential therapeutic target in cervical cancer.